Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 154, Issue 4, Pages 482-485Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1365-2141.2011.08752.x
Keywords
acute lymphoblastic leukaemia; childhood leukaemia; chemotherapy
Categories
Funding
- Medical Research Council [G0300130] Funding Source: researchfish
- MRC [G0300130] Funding Source: UKRI
- Medical Research Council [G0300130] Funding Source: Medline
Ask authors/readers for more resources
Clofarabine is a second-generation purine nucleoside analogue, which has shown promising activity in relapsed and refractory paediatric acute lymphoblastic leukaemia (ALL). This report summarizes the early United Kingdom experience of clofarabine for the treatment of paediatric ALL in 23 patients, outside of the context of a clinical trial. Our results demonstrated that clofarabine-based chemotherapy regimes were effective and well-tolerated in this heavily pre-treated group, with an overall response rate of 67% when used in combination regimes. Responses were seen in both B and T cell disease and in patients with adverse cytogenetics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available